Wolverine Trading, LLC United Therapeutics Corp Transaction History

Wolverine Trading, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$203.3 - $244.17 $218,344 - $262,238	1,074 New	1,074 $223,000
Q3 2021 Nov 12, 2021	SELL	$179.86 - $214.88 $361,338 - $431,693	-2,009 Reduced 45.46%	2,410 $447,000
Q2 2021 Aug 06, 2021	BUY	$170.47 - $211.93 $319,972 - $397,792	1,877 Added 73.84%	4,419 $782,000
Q1 2021 May 14, 2021	SELL	$153.94 - $174.85 $55,110 - $62,596	-358 Reduced 12.34%	2,542 $421,000
Q4 2020 Feb 12, 2021	BUY	$101.87 - $151.79 $295,423 - $440,191	2,900 New	2,900 $431,000
Q4 2019 Feb 12, 2020	SELL	$78.31 - $95.34 $193,660 - $235,775	-2,473 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$74.85 - $85.99 $609,653 - $700,388	-8,145 Reduced 76.71%	2,473 $200,000
Q1 2018 May 15, 2018	SELL	$107.21 - $151.94 $781,132 - $1.11 Million	-7,286 Reduced 40.69%	10,618 $1.19 Million
Q4 2017 Feb 14, 2018	BUY	$118.58 - $151.28 $1.92 Million - $2.44 Million	16,152 Added 921.92%	17,904 $2.65 Million
Q3 2017 Nov 15, 2017	BUY	$114.6 - $136.81 $200,779 - $239,691	1,752	1,752 $205,000

671

42.3M

194K

295K

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $16.4B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Trading, LLC with notifications on news.